Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor
- PMID: 40861796
- PMCID: PMC12375963
- DOI: 10.33393/jcb.2025.3564
Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor
Abstract
Introduction: Blood biomarkers play a crucial role in the diagnosis and prognosis of tumor. The present research was designed to study the diagnostic effect of serum biomarkers, namely carcino-embryonic antigen (CEA), cancer antigen 15-3 (CA15-3), and plasma biomarker viz., circulating cell-free DNA (cfDNA); and their correlation with cytological and histopathological results.
Methods: A total of 60 blood samples were collected. Out of which 36 samples were from the dogs affected with canine mammary tumors, and 24 samples were from the apparently healthy dogs. CEA and CA15-3 were estimated using Sandwich ELISA, and cfDNA was estimated by the ccfDNA kit. A significant Positive correlation was observed between tumor blood biomarker levels, cytology and histopathological grades of the tumors.
Results: We found that CA15-3 can be a more effective serum tumour biomarker than CEA for diagnosing canine mammary gland tumours. This finding showed a positive correlation with the clinical grade of the disease. The concentration of serum markers and cfDNA in animals affected with malignant mammary gland tumours was higher compared to the benign entity of tumours and healthy control groups. The ROC curve analysis revealed that the sensitivity (Se) and specificity (Sp) of CEA and CA15-3 biomarkers improved when used together. IN comparison to healthy controls, canines with both benign and malignant neoplasia showed significantly higher (p < 0.05) cfDNA concentrations.
Conclusion: This study highlights the role of blood tumor biomarkers for routine screening of animals in early diagnosis of tumors, further treatment, and prognosis.
Keywords: CA15-3; CEA; Cytology; Histopathology; Mammary gland tumors; cfDNA.
© 2025 The Authors.
Conflict of interest statement
Conflict of interest: The authors declare that they have no potential conflicts of interest.
Figures




Similar articles
-
Evaluation of serum CA15-3, CEA, Ki-67, PDL-1 and VEGF as a potential diagnostic and prognostic biomarkers in canine mammary tumors.Theriogenology. 2025 Nov;247:117579. doi: 10.1016/j.theriogenology.2025.117579. Epub 2025 Jul 15. Theriogenology. 2025. PMID: 40690828
-
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21. Clin Orthop Relat Res. 2025. PMID: 38905450
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2. Cochrane Database Syst Rev. 2016. PMID: 26930463 Free PMC article.
References
-
- Reif J. In: Withrow & MacEwen’s Small Animal Clinical Oncology. 5th ed. Withrow SJ, Vail DM, Page RL, editors. Saunders Elsevier;; 2007. The epidemiology and incidence of cancer. pp. 68–76. - DOI
LinkOut - more resources
Full Text Sources
Research Materials